YLIU-4-105-1
YLIU-4-105-1 is a Type II JAK2 inhibitor. YLIU-4-105-1 binds to the ATP-binding pocket of JH1. YLIU-4-105-1 has in vivo pharmacodynamic activity as evidenced by inhibiting pSTAT5, reducing spleen to body weight, and lowering blood reticulocyte counts in a dose-dependent manner[1].
Product Specifications
CAS Number
2417685-83-5
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/yliu-4-105-1.html
Concentration
10mM
Purity
99.39
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(C2=NN3C=C(NC(C4CC4)=O)N=C3C=C2)=C(C)C=C1)NC5=CC(C(F)(F)F)=CC(CN6CCN(CC6)CC)=C5
Molecular Formula
C32H34F3N7O2
Molecular Weight
605.65
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TGF-beta (1D11.16.8), CF740 conjugate, 0.1mg/mL
ACTH (Adrenocorticotrophic Hormone) (AH26), CF640R conjugate, 0.1mg/mL
Calbindin 1 (CALB1) (CALB1/2782), CF405S conjugate, 0.1mg/mL
CD43 (T-Cell Marker) (rSPN/839), CF488A conjugate, 0.1mg/mL
